Qiagen N.v. · NYSE:QGEN
Qiagen — Baird Conference 2025
51 slides from Qiagen's conference presentation, Sep 3, 2025
Slide 1: Committed to solid profitable growth: Investor Introduction
Committed to solid profitable growth Investor Introduction Q3 2025 Presentation Titel
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Investor Introduction Presentation Titel 3
Slide 4: QIAGEN solutions are used worldwide by researchers
QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs Investor Introduction Presentation Titel 4
Slide 5: QIAGEN more focused and stronger than ever
QIAGEN more focused and Growth and value stronger than ever ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN (2028) Sciences Diagnostics market customers (2024) ~50% ~50% QIAGEN product Sample technologies Balanced global presence 2024 net sales (%) groups 52 33 15
Slide 6: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #3 Life Sciences Customers Molecular Diagnostics Custo
Slide 7: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 8: Focusing on attractive opportunities in molecular testing
Focusing on attractive opportunities in molecular testing Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2024 sales $642 mn $749 mn $300 mn $234 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #3 QIAGEN #
Slide 9: QIAcuity dPCR capturing share from qPCR and NGS
QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy Lower sensitivity High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Capturin
Slide 10: Targeting research to clinical healthcare
Targeting research to clinical healthcare Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight >2,700 cumulative placements since launch Academia Overcoming entry barrier vs. qPCR Translational and Ease of use Fully integrated cancer resea
Slide 11: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase Add >100 assays QIAcuity-Dx of sales specialists for market menu expansion for CGT and enabling MRD and monitoring penet
Slide 12: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed Day 1 Day 1 One test within and ease o
Slide 13: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >4,600 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader qPCR rob
Slide 14: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Submitted to FDA Low-throughput High-throughput c
Slide 15: QIAGEN Digital Insights unlocking the power of genomics
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 16: Top bioinformatics for research to clinical customers
Top bioinformatics for research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech 6 Academia Sample prep Library prep NGS an
Slide 17: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 24 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 18: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 19: Focus on SaaS subscription model and AI to expand market leadership
Focus on "SaaS" subscription model and AI to expand market leadership 2028 goals Coming in 2025 Deepen global commercial reach and +40% 3 new AI product SaaS transition for sustainable growth SaaS sales specialists enhancements >14 10+ new DATA Invest in new AI technologies AI-enabled applications S
Slide 20: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, proteomics and m
Slide 21: Sample technologies
Sample technologies Laboratory workflow Differentiated solutions for PCR Valuable Biological Sample modular, integrated workflows molecular sample technologies insights Fast time to result, scalability Critical step in and ease of use dPCR High-quality molecular sample prep key to workflows Platform
Slide 22: Leader in the first step of lab workflows
Leader in the first step of lab workflows Key achievements Comprehensive Any >350 DNA / RNA consumables portfolio biological sample different sample kits target analytes >120 mn QIAGEN preparations e.g., tissue, cells, blood, for manual and sold per year including variations serum, wastewater automa
Slide 23: On the offense expanding our top automation portfolio
On the offense expanding our top automation portfolio Low-throughput Mid-throughput High-throughput ≥$750 mn Sample technologies net sales CER target (2028) QIAmini QIAsymphony QIAsprint Connect Connect Launch 2026 Launch 2025 Launch 2026 Addition to QIAcube / EZ Flagship system upgrade, Market Entr
Slide 24: QuantiFERON
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infection patients North America Japan >75 mn A
Slide 25: Best-positioned test for latent TB detection
Best-positioned test for latent TB detection QuantiFERON Tuberculin Key achievements Advantages over Specification blood test skin test skin test $454 mn Customizable automated workflow High accuracy and specificity 2024 net sales (+89% vs. 2019) Only one patient visit Electronic results >125 mn Qua
Slide 26: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in skin
Slide 27: Initiatives to fuel growth investments and achieve margin
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >6 million ~30 website
Slide 28: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers Great Great Great Great Great Great ~5,700 Place Place Place Place Place Place To To To To To To Work ® Work ® Work ® Work ® Work ® Work ® Certified Certificada Certificada Certified Certified Certified QIAGENers NOV 2023–NOV 2024 DEC 2022–DEC 2023 OCT
Slide 29: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2024) Serving society >50 public health partnerships (2024) Business with integrity ~8,000 compliance trainings completed (2024) Investor
Slide 30: Disciplined capital allocation to create value
Disciplined capital allocation to create value Profitable targeted investments Annual dividend Organic payment investments Into growth pillars and digitization to fuel profitable business expansion First-ever dividend totaling $54 mn paid in July 2025 after AGM approval Focused Value-creating transa
Slide 31: Q2 2025 results
Q2 2025 results Solid performance exceeding outlook August 5, 2025
Slide 32: Q2 2025: Solid performance exceeding outlook
Q2 2025: Solid performance exceeding outlook Growth Solid performance with continued strength across the portfolio $534 mn ($526 mn CER) • Net sales +6% CER to $534 mn ahead of outlook for ~+5%; core sales +6% CER Net sales • QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) lead pillars, while autom
Slide 33: Q2 2025: Sales performance and key developments
Q2 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +6% Sample • Steady CER sales as automated kits offset soft manual kits CER(1) technologies • Instrument placements led by QIAsymphony and EZ2 systems 496 534 Sample • +11% CER gro
Slide 34: Q2 2025: Portfolio developments
Q2 2025: Portfolio developments Sample technologies: QIAcuity: QIAGEN Digital Insights: Advancing automated sample preparation Advancing cell therapy analytics Advancing genomic insights for clinicians Three new instruments progressing Expanded dPCR portfolio for lentiviral Genoox adds Franklin clou
Slide 35: Q2 2025: Ongoing solid profitability improvements
Q2 2025: Ongoing solid profitability improvements Adj. operating income margin Adj. EPS ahead of Q2 2025 outlook Adj. +13% to $160 million on efficiency operating gains and NeuMoDx discontinuation +1.5 ppt 29.9% income 28.4% Non- operating 20% adj. tax rate above ~19% target income $0.60 Adj. EPS(1)
Slide 36: H1 2025: Continuous high cash flow
H1 2025: Continuous high cash flow Cash flow(1) Debt maturity overview(3) updated August 28, 2025 (in $ millions) In $ millions Q2 2025 Q2 2024 Change Operating cash flow 161 167 -3% 770 Purchases of PP&E(2) -40 -38 +5% 624 Free cash flow 121 129 -6% 124 500 Likely repayment in 2025(4) 500 750 164 I
Slide 37: Outlook: Q3 and FY 2025
Outlook: Q3 and FY 2025 As of August 1, 2025 Outlook Q3 2025 FY 2025 Net sales ≥+4% CER / +4-5% CER(2) / ≥+5% CER core portfolio(1) +5-6% CER core portfolio(1,3) Anticipated currency impact Positive impact of <+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS ≥$0.58 CER ~$2.35 CER Anticipated c
Slide 38: Appendix
QIAGEN Appendix
Slide 39: Q2 and FY 2025: Outlook and assumptions
Q2 and FY 2025: Outlook and assumptions (As of August 1, 2025) Q3 2025 outlook FY 2025 outlook Net sales ≥+4% CER / ≥+5% CER core portfolio(1) +4-5% CER / +5-6% CER core portfolio(1) (Previously ~+4% CER / ~+5% CER core portfolio) Anticipated currency impact(2) Positive impact of <+1 ppt Positive im
Slide 40: Q2 2025: Consolidated Statements of Income
Q2 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended June 30, 2025 June 30, 2024 Net sales 533,540 496,347 Cost of sales: Cost of sales 185,951 446,371 Acquisition-related intangible amortization 13,303 15,212 Total cost of
Slide 41: H1 2025: Consolidated Statements of Income
H1 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Six months ended Six months ended June 30, 2025 June 30, 2024 Net sales 1,016,996 955,143 Cost of sales: Cost of sales 347,245 598,105 Acquisition-related intangible amortization 26,784 31,285 Total cost of sa
Slide 42: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 316 -1% -1% Diagnostic solutions(1) 187 9%
Slide 43: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 911 7% 7% revenue
Slide 44: Q2 and H1 2025: Reconciliation to adjusted results
Q2 and H1 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Second quarter 2025 Reported results 533.5 334.3 121.9 126.8 (30.6) 24 % 96.2 0.44 Adjustments Business integr
Slide 45: Footnotes for reconciliation to adjusted results
Q2 and H1 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025. It also includes costs incurred in connection with streamlining operati
Slide 46: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 1,017.0 Net sales (CER) 491.2 525.8 1,016.9 Gross profit 308.7 334.3 643.0 Gross profit margin 63.8% 62.7% 63.2% Adjusted gross profit
Slide 47: Consolidated Balance Sheets
Consolidated Balance Sheets (unaudited) December 31, December 31, (In $ thousands, except par value) June 30, 2025 2024 (In $ thousands, except par value) June 30, 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 733,815 663,555 Current portion of long-term debt
Slide 48: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended (In $ thousands) June 30, 2025 June 30, 2024 (In $ thousands) June 30, 2025 June 30, 2024 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 187,008 (102,787) Capital repaym
Slide 49: Q2 and H1 2025: Currency impact
Q2 and H1 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2025 U.S. dollar 295.8 295.9 56% 0.1 Euro 112.5 106.6 20% -5.9 British pound 17.5 16.6 3% -0.9 Japanese yen 9.2 8.5 2% -0.7 Other currencies 98.6 98.2 19
Slide 50: Employees as of June 30, 2025
Employees as of June 30, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q2 2025 Q1 2025 Change Production 300 1,123 147 1,570 1,728 -9% R&D 165 773 55 993 847 17% Sales 549 840 715 2,104 2,101 0% Marketing 68 177 74 319 327 -2% Administration 79 444 153 676 670 1%
Slide 51: Your contacts
Your contacts Dr. Domenica Martorana Calendar Associate Director E-mail: Global Investor Relations Q3 2025 results November 2025 ir@qiagen.com Phone: +49 2103 29 11244 Internet: Q4 2025 results February 2026 E-mail: domenica.martorana@qiagen.com corporate.QIAGEN.com Alexandra Koenig Share informatio